EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone ( IRd ) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03

Aurore Perrot iD, Murielle Roussel, Valerie Lauwers-Cances, Cyrille Hulin iD, Xavier Leleu iD, Cyrille Touzeau iD, Thierry Facon, Clara Mariette, Jean-Marc Schiano, Julie Gay, Lydia Montes iD, Dana Ranta und 8 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19570 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Aurore Perrot und 19 weiteren Autor:innen. Beteiligte Einrichtung: Service Hématologie, Toulouse University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Lenalidomide, Multiple Myeloma, Dexamethasone, Glycine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Takeda Pharmaceutical Company, Intergroupe Francophone du Myélome, Paris, France.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic strategies for patients with newly diagnosed multiple myeloma (NDMM) have considerably improved during the last 10 years. The IFM2014‐03 trial proposed an all‐oral triplet induction/consolidation regimen in transplant‐eligible NDMM patients, followed by lenalidomide maintenance. Induction consisted of three 21‐day cycles of ixazomib, lenalidomide and dexamethasone (IRd), before high‐dose Melphalan with transplant followed by eight 28‐day cycles of IRd consolidation before 13 cycles of lenalidomide maintenance. Forty‐six patients were enrolled and received at least one dose of therapy, and 39 entered the maintenance phase. The primary end‐point was stringent complete response after consolidation, and was achieved in nine patients (20.9%, 90% CI 11.4–33.7; p = 0.998). Ten patients (24.4%) had an undetectable minimal residual disease. The overall response rate was 95.7%. The 3‐year progression‐free survival was 66.3%. No unexpected toxicities were recorded, and only eight patients suspended from any study drug. Of note, 21 (45.7%) patients reported peripheral neuropathy (PN) (grades 1–2 with no serious adverse events). IRd induction and consolidation with transplant before lenalidomide maintenance shows lower response rates compared to other triplet therapies. It could be an alternative for patients who require an all‐oral regimen and/or with pre‐existent PN, especially if quadruplet regimens including anti‐CD38 antibody are not available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideMultiple MyelomaDexamethasoneGlycineAntineoplastic Combined Chemotherapy ProtocolsBoron CompoundsHumansMiddle AgedFemaleMaleAgedAdultConsolidation ChemotherapyMaintenance ChemotherapyHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

clinical trialsmultiple myelomatransplant

Substanzen

LenalidomideDexamethasoneGlycineixazomibBoron Compounds

Autor:innen und Institutionen

  • Service Hématologie, Toulouse University Hospital, Toulouse, France.
  • Service Hématologie, Limoges University Hospital, Limoges, France.
  • UMSR, Toulouse University, Toulouse, France.
  • Service Maladies du Sang, Bordeaux University Hospital, Bordeaux, France.
  • Service Hématologie, Poitiers University Hospital, Poitiers, France.
  • Service Hématologie, Nantes University Hospital, Nantes, France.

ORCID-Profile: Aurore Perrot, Cyrille Hulin, Xavier Leleu, Cyrille Touzeau, Lydia Montes, Jill Corre, Philippe Moreau

Förderung

  • Bristol-Myers Squibb
  • Takeda Pharmaceutical Company
  • Intergroupe Francophone du Myélome, Paris, France

Zitieren

APA

Perrot, A., Roussel, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Touzeau, C., Facon, T., Mariette, C., Schiano, J. M., Gay, J., Montes, L., Ranta, D., Huguet, A., Wuillème, S., Dejoie, T., Devlamynck, L., Corre, J., Avet-Loiseau, H., Moreau, P., & Attal, M. (2024). Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone ( IRd ) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03. British Journal of Haematology. https://doi.org/10.1111/bjh.19570

Vancouver

Perrot A, Roussel M, Lauwers-Cances V, Hulin C, Leleu X, Touzeau C, et al. Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone ( IRd ) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03. British Journal of Haematology. 2024. doi:10.1111/bjh.19570

BibTeX
@article{Perrot2024,
  author = {Perrot, Aurore and Roussel, Murielle and Lauwers-Cances, Valerie and Hulin, Cyrille and Leleu, Xavier and Touzeau, Cyrille and Facon, Thierry and Mariette, Clara and Schiano, Jean-Marc and Gay, Julie and Montes, Lydia and Ranta, Dana and Huguet, Amandine and Wuillème, Soraya and Dejoie, Thomas and Devlamynck, Laure and Corre, Jill and Avet-Loiseau, Hervé and Moreau, Philippe and Attal, Michel},
  title = {Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone ( IRd ) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19570}
}
Kostenlos starten →